Cargando…

Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer

The treatment effects of metastasis-directed therapy in patients with oligometastatic disease have received much attention. In our case, a 72-year-old man with oligometastatic castration-resistant prostate cancer was referred to our hospital. The patient had undergone radical radiotherapy with a tot...

Descripción completa

Detalles Bibliográficos
Autores principales: Katano, Atsuto, Yamashita, Hideomi, Nakagawa, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943180/
https://www.ncbi.nlm.nih.gov/pubmed/33717741
http://dx.doi.org/10.7759/cureus.13199
_version_ 1783662440497545216
author Katano, Atsuto
Yamashita, Hideomi
Nakagawa, Keiichi
author_facet Katano, Atsuto
Yamashita, Hideomi
Nakagawa, Keiichi
author_sort Katano, Atsuto
collection PubMed
description The treatment effects of metastasis-directed therapy in patients with oligometastatic disease have received much attention. In our case, a 72-year-old man with oligometastatic castration-resistant prostate cancer was referred to our hospital. The patient had undergone radical radiotherapy with a total dose of 76 Gy in 36 fractions for localized prostate cancer nine years prior to the first visit. Positron emission tomography showed a slight increase in accumulation in the para-aortic lymph nodes. The patient received conventional radiotherapy at a total dose of 50 Gy in 25 fractions to the para-aortic region as oligometastasis-directed local therapy. After radiotherapy, his prostate-specific antigen (PSA) level decreased slightly, but it increased again soon after. According to the results of positron emission tomography, the accumulation around the para-aortic lymph nodes had decreased; however, a slight increase in accumulation in the sub/supra-clavicular lymph nodes was observed. He received radiotherapy at a total dose of 50 Gy in 25 fractions to the sub/supra-clavicular region. We confirmed a significant reduction in lesion volume and a downward trend in PSA levels. Metastasis-directed therapy has shown remarkable effectiveness in controlling disease without severe treatment-related adverse events. Metastasis-directed therapy is considered as one of the treatment options in patients who need salvage therapy.
format Online
Article
Text
id pubmed-7943180
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-79431802021-03-12 Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer Katano, Atsuto Yamashita, Hideomi Nakagawa, Keiichi Cureus Radiation Oncology The treatment effects of metastasis-directed therapy in patients with oligometastatic disease have received much attention. In our case, a 72-year-old man with oligometastatic castration-resistant prostate cancer was referred to our hospital. The patient had undergone radical radiotherapy with a total dose of 76 Gy in 36 fractions for localized prostate cancer nine years prior to the first visit. Positron emission tomography showed a slight increase in accumulation in the para-aortic lymph nodes. The patient received conventional radiotherapy at a total dose of 50 Gy in 25 fractions to the para-aortic region as oligometastasis-directed local therapy. After radiotherapy, his prostate-specific antigen (PSA) level decreased slightly, but it increased again soon after. According to the results of positron emission tomography, the accumulation around the para-aortic lymph nodes had decreased; however, a slight increase in accumulation in the sub/supra-clavicular lymph nodes was observed. He received radiotherapy at a total dose of 50 Gy in 25 fractions to the sub/supra-clavicular region. We confirmed a significant reduction in lesion volume and a downward trend in PSA levels. Metastasis-directed therapy has shown remarkable effectiveness in controlling disease without severe treatment-related adverse events. Metastasis-directed therapy is considered as one of the treatment options in patients who need salvage therapy. Cureus 2021-02-07 /pmc/articles/PMC7943180/ /pubmed/33717741 http://dx.doi.org/10.7759/cureus.13199 Text en Copyright © 2021, Katano et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Radiation Oncology
Katano, Atsuto
Yamashita, Hideomi
Nakagawa, Keiichi
Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
title Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
title_full Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
title_fullStr Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
title_full_unstemmed Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
title_short Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
title_sort metastasis-directed radiotherapy for oligometastatic castration-resistant prostate cancer
topic Radiation Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943180/
https://www.ncbi.nlm.nih.gov/pubmed/33717741
http://dx.doi.org/10.7759/cureus.13199
work_keys_str_mv AT katanoatsuto metastasisdirectedradiotherapyforoligometastaticcastrationresistantprostatecancer
AT yamashitahideomi metastasisdirectedradiotherapyforoligometastaticcastrationresistantprostatecancer
AT nakagawakeiichi metastasisdirectedradiotherapyforoligometastaticcastrationresistantprostatecancer